Oleic acid in the absence of a PPARγ agonist increases adipogenic gene expression in bovine muscle satellite cells1

• Published in: Journal of animal science Vol. 97; no. 10; pp. 4114 - 4123
• Main Authors: Li, Xiang Z, Yan, Yan, Zhang, Jun F, Sun, Jian F, Sun, Bin, Yan, Chang G, Choi, Seong H, Johnson, Bradley J, Kim, Jong K, Smith, Stephen B
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 03-10-2019
• Subjects: Adipogenesis - genetics; Adiponectin - analysis; Animals; Cattle; Cell and Molecular Biology; Cell Differentiation; Cells, Cultured; Culture Media; Down-Regulation; Fluorescent Antibody Technique; Gene Expression; Lipid Metabolism - genetics; Muscle Development - genetics; Myogenin - genetics; Myogenin - metabolism; Oleic Acid - administration & dosage; PPAR gamma - agonists; PPAR gamma - genetics; PPAR gamma - metabolism; RNA - analysis; RNA - isolation & purification; Satellite Cells, Skeletal Muscle - cytology; Satellite Cells, Skeletal Muscle - metabolism; Stearoyl-CoA Desaturase - metabolism; Sterol Regulatory Element Binding Protein 1 - genetics; Sterol Regulatory Element Binding Protein 1 - metabolism; Thiazolidinediones - pharmacology; Triglycerides - analysis; Triglycerides - metabolism; bovine; adipocytes; muscle; oleic acid; ciglitazone; satellite cells
• ISSN: 0021-8812; 1525-3163
• DOI: 10.1093/jas/skz269

Abstract
We hypothesized that oleic acid (OA) in the absence of a thiazolidinedione (i.e., a synthetic peroxisome proliferator-activated receptorγ [PPARγ] agonist) would increase adipogenic gene expression in bovine muscle satellite cells (BSC). The BSC were cultured in differentiation medium containing 10 µM ciglitazone (CI), 100 µM OA, or 100 µM OA plus 10 µM CI (CI-OA). Control (CON) BSC were cultured only in differentiation media (containing 2% horse serum). The presence of myogenin, desmin, and paired box 7 proteins was confirmed in the BSC by immunofluorescence staining, demonstrating that we had isolated myogenic cells. The OA BSC had lesser paired box 3 (Pax3) and myogenic differentiation 1 expression but greater Pax7 and mygogenin (MYOG) expression (P < 0.05), than the CON BSC. The CI BSC had greater Pax3, Pax7, and MYOG expression than CON BSC (P < 0.05), suggesting that CI would promote BSC myogenesis under pro-myogenic conditions (i.e., when cultured with horse serum). However, both the OA and CI treatments upregulated the expression of PPARγ, CCAAT/enhancer-binding protein alpha (C/EBPα) and C/EBPß, sterol regulatory element-binding protein 1, lipoprotein lipase, and glycerol-3-phosphate acyltransferase 3 gene expression, as well as media adiponectin concentration (P < 0.05). The CI, OA, and CI-OA treatments also increased triacylglycerol and lipid droplet accumulation, in spite of upregulation (relative to CON BSC) of adenosine monophosphate-activated protein kinase alpha-1, perilipin 2 (PLIN2), and PLIN3 in BSC and downregulation of G protein-coupled protein receptor 43, acyl-CoA synthetase long chain family member 3, and stearoyl-CoA desaturase (P < 0.05). These results indicate that OA in the absence of a synthetic PPARγ agonist can effectively increase adipogenic gene expression in BSC.